Application of a Human Immune System-Reconstituted Mouse Model of Lupus in Evaluating the Efficacy of B Cell-Targeting Therapies (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1100; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Biologics designed to deplete pathogenic B cells, such as Rituximab (CD20 monoclonal antibody) and Blincyto (CD19-directed T Cell Engager) have demonstrated promising therapeutic efficacy in clinical trials. The humanized lupus model recapitulates key pathological features of SLE, including elevated autoantibodies and pathogenic B cells, making it a valuable tool for evaluating the efficacy of B cell-directed therapeutics."
Preclinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Juan Liang; Yinlian Zhang
|